Opinion|Videos|December 29, 2023

Clinical Data on the Approved JAK Inhibitors for Treatment of Myelofibrosis

An expert discusses the four FDA-approved JAK inhibitors for myelofibrosis - ruxolitinib, fedratinib, pacritinib, and momelotinib.

Related to this article

Image of Ramshaw
After a pancreatic cancer diagnosis upended his life and career, one survivor reflects on treatment, resilience and finding hope more than a decade later.